Cefotaxime sodium - søkeresultat

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

dbl™ cefotaxime sodium for injection

pfizer new zealand limited - cefotaxime sodium 525mg equivalent to 500 mg cefotaxime; ; - powder for injection - 500 mg - active: cefotaxime sodium 525mg equivalent to 500 mg cefotaxime - dbl™ cefotaxime sodium for injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemia. respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft tissue infections: cellulitis, peritonitis and wound infections. bone and joint infections: osteomyelitis, septic arthritis. obstetric and gynaecological infections: pelvic inflammatory disease. gonorrhoea: particularly if penicillin-resistant. other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of dbl™ cefotaxime sodium for injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. dbl™ cefotaxime sodium for injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cefotaxime noridem 0,5 g sol. inj./perf. (pdr.) i.v. flac.

noridem enterprises ltd. - céfotaxime sodique 524 mg - eq. céfotaxime 500 mg - poudre pour solution injectable/pour perfusion - 0,5 g - céfotaxime sodique 524 mg - cefotaxime

USA - engelsk - NLM (National Library of Medicine)

cefotaxime injection, powder, for solution

wockhardt limited - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime sodium 500 mg in 1 ml - - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species , haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae, proteus mirabilis, serratia marcescens*, enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). - genitourinary infections. urinary tract infections caused by enterococcus species, staphylococcus epidermidis, staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobacter species, escherichia coli , klebsiella species, proteus mirabilis, proteus vulgaris*, providencia stuartii, morganella morganii*, providencia rettgeri*, serratia marcescens and pseudomonas s

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cefotaxime sandoz cefotaxime 2g powder for injection vial

sandoz pty ltd - cefotaxime sodium, quantity: 2096.4 mg (equivalent: cefotaxime, qty 2000 mg) - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower); infections of the urinary tract; septicaemia (concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism); intra-abdominal infection; gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoea); ear, nose and throat infections; skin and skin structure infections; bone and joint infections; meningitis: cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or benzylpenicillin) for initial therapy in children (excluding neonates) pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infec